Compare Nano Dimension Ltd - ADR (NNDM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Twist Bioscience Corp — how do they compare? Nano Dimension Ltd - ADR trades at $1.51 (market cap $315.88M), while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Twist Bioscience Corp is far larger — about 26.1× Nano Dimension Ltd - ADR's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| NNDM | TWST | |
|---|---|---|
Market Cap | $315.88M | $8.26B |
Sector | Technology | Health |
52-Week High | $2.14 | $153.10 |
52-Week Low | $1.21 | $24.16 |
Enterprise Value | -$88.96M | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.555, down 4.01% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $121M but a net loss of -$163M, reflecting a net margin of -135.18%. Recent strategic moves include appointing a new board member and cost-saving initiatives aimed at reducing cash burn by $25M annually. The balance sheet shows a strong cash position of $757.96M with minimal debt, but operating cash flow remains negative.
The outlook is cautious due to persistent losses and high cash burn, though asset sales and cost cuts may improve liquidity. Investment opportunity lies in the company's cash reserves and potential strategic shifts, but risks include ongoing operational losses and shareholder activism. The stock faces pressure from weak profitability and bearish technical trends.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
